BridgeBio Pharma Inc to Discuss Phase 2 Data for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)- Conference Call Transcript
Good day, and thank you for standing by. Welcome to the BridgeBio Pharma to discuss Phase II data for BBP-418 in limb-girdle muscular dystrophy Type 2i conference call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions) And now I would like to hand the conference over to Mr. Neil Kumar, CEO of BridgeBio Pharma. Thank you. Please go ahead, sir.
Well, thank you so much, operator, and thanks, everyone, for joining us as we discuss some exciting new data from our program targeting the disease, the large and devastating to the limb-girdle muscular dystrophy Type 2i. Before we begin, I just want to make a quick reminder. We'll be making some forward-looking statements today, which are based on our current expectations and beliefs. As such, these statements are subject to certain risks and uncertainties, and I'd encourage everyone, as you know, to consult the section entitled Risk Factors in our most recent annual report on Form 10-K
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |